Dempze Nancy E Trims Holdings in Johnson & Johnson (NYSE:JNJ)

Dempze Nancy E lowered its stake in Johnson & Johnson (NYSE:JNJ - Free Report) by 9.8% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 22,624 shares of the company's stock after selling 2,462 shares during the period. Johnson & Johnson accounts for 2.3% of Dempze Nancy E's holdings, making the stock its 19th biggest position. Dempze Nancy E's holdings in Johnson & Johnson were worth $3,752,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently made changes to their positions in the company. WealthTrak Capital Management LLC purchased a new stake in Johnson & Johnson in the fourth quarter valued at $26,000. Conquis Financial LLC purchased a new stake in shares of Johnson & Johnson in the fourth quarter worth about $33,000. Bernard Wealth Management Corp. acquired a new stake in Johnson & Johnson during the fourth quarter worth about $36,000. Highline Wealth Partners LLC lifted its holdings in Johnson & Johnson by 51.8% in the first quarter. Highline Wealth Partners LLC now owns 252 shares of the company's stock valued at $42,000 after acquiring an additional 86 shares during the period. Finally, von Borstel & Associates Inc. purchased a new stake in Johnson & Johnson in the 1st quarter worth approximately $49,000. 69.55% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

JNJ has been the subject of several recent research reports. Guggenheim lifted their target price on shares of Johnson & Johnson from $164.00 to $167.00 and gave the company a "neutral" rating in a report on Thursday, July 17th. Barclays increased their target price on shares of Johnson & Johnson from $165.00 to $176.00 and gave the stock an "equal weight" rating in a research note on Thursday, July 17th. Piper Sandler reaffirmed an "overweight" rating on shares of Johnson & Johnson in a report on Thursday, July 17th. Morgan Stanley boosted their price objective on Johnson & Johnson from $171.00 to $176.00 and gave the company an "equal weight" rating in a research report on Thursday, July 17th. Finally, Leerink Partners cut shares of Johnson & Johnson from an "outperform" rating to a "market perform" rating and dropped their price target for the company from $169.00 to $153.00 in a research note on Tuesday, May 13th. Nine analysts have rated the stock with a hold rating, ten have assigned a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $174.50.

Johnson & Johnson Trading Up 0.3%

Shares of JNJ traded up $0.52 during midday trading on Thursday, reaching $169.62. The company had a trading volume of 6,629,361 shares, compared to its average volume of 8,401,730. The firm has a 50 day simple moving average of $155.75 and a 200-day simple moving average of $155.63. The company has a quick ratio of 1.03, a current ratio of 1.26 and a debt-to-equity ratio of 0.49. The stock has a market cap of $408.11 billion, a PE ratio of 18.14, a price-to-earnings-growth ratio of 2.15 and a beta of 0.41. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $169.99.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, beating the consensus estimate of $2.68 by $0.09. The company had revenue of $23.74 billion for the quarter, compared to analyst estimates of $22.85 billion. Johnson & Johnson had a net margin of 25.00% and a return on equity of 33.07%. Johnson & Johnson's revenue was up 5.8% on a year-over-year basis. During the same period in the previous year, the business posted $2.82 EPS. Research analysts forecast that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th will be given a $1.30 dividend. The ex-dividend date is Tuesday, August 26th. This represents a $5.20 dividend on an annualized basis and a yield of 3.07%. Johnson & Johnson's dividend payout ratio is currently 55.61%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.